APA (7th ed.) Citation

Pai‐Scherf, L., Blumenthal, G. M., Li, H., Subramaniam, S., Mishra‐Kalyani, P. S., He, K., . . . Pazdur, R. (2017). FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond. The oncologist (Dayton, Ohio), 22(11), 1392-1399. https://doi.org/10.1634/theoncologist.2017-0078

Chicago Style (17th ed.) Citation

Pai‐Scherf, Lee, et al. "FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond." The Oncologist (Dayton, Ohio) 22, no. 11 (2017): 1392-1399. https://doi.org/10.1634/theoncologist.2017-0078.

MLA (9th ed.) Citation

Pai‐Scherf, Lee, et al. "FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond." The Oncologist (Dayton, Ohio), vol. 22, no. 11, 2017, pp. 1392-1399, https://doi.org/10.1634/theoncologist.2017-0078.